SubsidieMeestersBiophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD aims to develop a non-invasive blood test using fluorescence lifetime analysis of personalized protein corona to enable early detection of pancreatic cancer, potentially reducing mortality rates significantly.
Projectdetails
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a deadly form of cancer that is on the rise due to various factors, including an aging population and unhealthy lifestyles. Regrettably, PDAC is among the top cancer killers, with a dismal five-year survival rate of less than 10%.
Challenges in Early Detection
The lack of adequate screening programs is a significant factor contributing to this dire statistic. However, the identification of PDAC in its early stages could help reduce the mortality rate by as much as 80%.
Project Overview
The project LASERBLOOD (Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer) aims to develop an in vitro diagnostic test based on the fluorescence lifetime fingerprint of the personalized protein corona, offering critical information at every stage of PDAC progression.
Understanding Protein Corona
The protein corona (PC) is a coating of bio-molecular substances surrounding nanoparticles when exposed to biofluids. It is both personalized and disease-specific, making it an ideal marker to monitor the variation of nanoparticle PC and correlate it to the development of PDAC.
Methodology
The analysis will use fluorescence lifetime (FL) analysis, a non-invasive, reactant-free, and real-time technique.
Initial Phase
- In the initial phase, the consortium will utilize a mouse model (MKC) to identify the FL fingerprint of protein corona at each stage of PDAC development.
- The MKC mouse model is genetically engineered to be bioluminescent and develop PDAC in a controlled manner.
- By linking the development of PDAC observed through bioluminescent imaging to the FL response of PC in blood samples, the consortium will provide an unprecedented fingerprint of the disease's progression from its first occurrence.
Second Stage
At a second stage, the project will validate on humans the use of the FL fingerprint of protein corona as a tool for the early diagnosis of PDAC.
Expected Outcomes
The findings will provide the scientific and technological foundation for the development of an in vitro PDAC test for large-scale screening of the population.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.988.461 |
| Totale projectbegroting | € 2.988.461 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 31-12-2027 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FLIM LABS SRLpenvoerder
- UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
- FONDAZIONE POLICLINICO UNIVERSITARIO CAMPUS BIO MEDICO
- UNIVERSITATSKLINIKUM ERLANGEN
- ISTITUTI FISIOTERAPICI OSPITALIERI
- CROWDHELIX LIMITED
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
Dynamic Spatio-Temporal Modulation of Light by Phononic ArchitecturesDynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements. | EIC Pathfinder | € 2.552.277 | 2022 | Details |
Emerging technologies for crystal-based gamma-ray light sourcesTECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology. | EIC Pathfinder | € 2.643.187 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures
Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.
Emerging technologies for crystal-based gamma-ray light sources
TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal AdenocarcinomaPROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity. | ERC COG | € 1.999.401 | 2023 | Details |
Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at riskThis project aims to develop and test liver-specific mRNA therapies targeting HNF4a to prevent or alleviate cancer-associated cachexia in pancreatic cancer patients identified by a novel liver score. | ERC POC | € 150.000 | 2023 | Details |
Actionable metabolite supplements to improve treatment response in pancreatic cancerThe ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients. | ERC POC | € 150.000 | 2024 | Details |
Early Inflammatory Signatures of IPMN ProgressionThis project aims to validate a gene signature as a biomarker for classifying IPMN patients' risk of progressing to PDAC, enhancing personalized treatment and early detection strategies. | ERC POC | € 150.000 | 2024 | Details |
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma
PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.
Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at risk
This project aims to develop and test liver-specific mRNA therapies targeting HNF4a to prevent or alleviate cancer-associated cachexia in pancreatic cancer patients identified by a novel liver score.
Actionable metabolite supplements to improve treatment response in pancreatic cancer
The ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients.
Early Inflammatory Signatures of IPMN Progression
This project aims to validate a gene signature as a biomarker for classifying IPMN patients' risk of progressing to PDAC, enhancing personalized treatment and early detection strategies.